CORDIS
EU research results

CORDIS

English EN

Minimizing Activity and Dose with Enhanced Image quality by Radiopharmaceutical Administrations

Project information

Grant agreement ID: 212100

Status

Closed project

  • Start date

    1 January 2008

  • End date

    31 December 2010

Funded under:

FP7-EURATOM-FISSION

  • Overall budget:

    € 3 948 824

  • EU contribution

    € 2 820 000

Coordinated by:

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany

Objective

MADEIRA aims to improve 3D nuclear medical imaging technologies significantly. Achievements will be made in terms of reduction of radiation exposure, increase of spatial and temporal resolution. In consequence, the applied techniques will offer better and more detailed pictures for diagnosis obtained with less exposure to radioactivity. Due to the introduction of new diagnostic procedures such as CT, PET and SPECT, the individual dose caused by medical exposures rapidly grew in the last years. This is especially a subject to radiation protection for nuclear medical diagnosis since in this case radiopharmaceuticals are administered to the patient meaning not only a radiation exposure to the unhealthy tissue but also to the healthy tissue of large parts of the body. When dealing with cancer any improvement in the efficacy and availability of proper diagnostic procedures turns out into a benefit for the patients. Early diagnosis reduces mortality and other serious implications like loss of quality of living or high therapy costs. Diagnosis that provides information about - activity of the cancerous tissue - in what 3D region of the cancer and - what kind of cancer to be treated in each specific case is very important. 3D functional nuclear medicine imaging satisfies the above requirements. Especially the combination of today’s systems with CT scanners allows simultaneous acquisition of anatomical and functional information. MADEIRA will improve the efficacy and safety of 3D PET and SPECT functional imaging by optimising the spatial resolution, the signal-to-noise ratio and the knowledge of the temporal variation of the radiopharmaceuticals’ uptake in and clearance from tumour and healthy tissues and evaluating the corresponding patient dose. By this approach to an optimized imaging procedure gaining more information per administered dose MADEIRA will especially reduce the dose to healthy tissue of the patient.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Address

Ingolstadter Landstrasse 1
85764 Neuherberg

Germany

Activity type

Research Organisations

EU Contribution

€ 663 673

Administrative Contact

Juergen Ertel (Dr.)

Participants (6)

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 337 490

INSTITUT JOZEF STEFAN

Slovenia

EU Contribution

€ 423 114

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 460 778

Scivis wissenschaftliche Bildverarbeitung GmbH

Germany

EU Contribution

€ 679 605

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 255 340

UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN

United States

Project information

Grant agreement ID: 212100

Status

Closed project

  • Start date

    1 January 2008

  • End date

    31 December 2010

Funded under:

FP7-EURATOM-FISSION

  • Overall budget:

    € 3 948 824

  • EU contribution

    € 2 820 000

Coordinated by:

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany